This announcement is for information purposes only and does not constitute an
offer to buy, sell, issue or subscribe any securities, and is not a
solicitation of an offer to buy, sell, issue or subscribe securities. 

As published, most recently in company announcement No. 22 of June13, 2013,
BioPorto A/S is planning to carry out a rights issue to existing shareholders. 


The Board expects to make a final decision on the issue and to publish the
prospectus in mid-August 2013. 

The issue is expected to include up to 70.7 million shares of nominal value DKK
1.00 at a subscription price of DKK 1.00. The shareholders will thus have
pre-emptive rights to new shares in the ratio 2:3 (equivalent to 2 existing
shares entitling the holder to subscribe for 3 new shares). The Board expects
to set a minimum for the issue of DKK 40 million meaning that the company could
raise gross proceeds of between DKK 40 million and DKK 70.7 million if the
issue is implemented. 

In connection with the issue, a number of shareholder meetings are planned on
the following dates: 

Tuesday August 13, 2013 in Copenhagen (assuming the prospectus is published
before this date) 

Tuesday August 27, 2013 in Aarhus

Wednesday August 28, 2013 in Copenhagen


Details of times, venues and registration will be published and made available
on the Company's website no later than the prospectus. 


This announcement contains forecasts for future development. Such statements
are inherently uncertain and involve risks because many factors - some of which
will be outside BioPortos control - could cause actual developments to differ
from the expectations contained in the message. 

For further information please contact:

Thea Olesen, CEO

Christina Thomsen, Investor Relations

Tel. +45 45 29 00 00, mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ OMX Copenhagen stock exchange.